To determine the efficacy and safety of adding ezetimibe to maximally tolerated lipid lowering therapy in patients with HIV dyslipidemia. Retrospective analysis of lipid parameters was conducted for 33 patients with HIV who had been prescribed ezetimibe 10 mg per day. Mean total cholesterol was reduced 21% (p < 0.001). Mean LDL was reduced 35% (p < 0.001). Mean HDL increased 8% (p = 0.038). Mean triglyceride was reduced 34% (p = 0.006). Mean Apolipoprotein B100 was reduced 33% (p = 0.043). No adverse events occurred. Ezetimibe appears safe and effective in patients with HIV when added to maximally tolerated doses of lipid lowering therapy.

译文

确定在HIV血脂异常患者中添加依折米布最大耐受降脂治疗的有效性和安全性。对33例每天服用依泽替米布10 mg的HIV患者进行了脂质参数的回顾性分析。平均总胆固醇21% 降低 (p <0.001)。平均LDL 35% 降低 (p <0.001)。平均HDL 8% 增加 (p = 0.038)。平均甘油三酯34% 降低 (p = 0.006)。平均载脂蛋白B100 33% 降低 (p = 0.043)。无不良事件发生。当添加到最大耐受剂量的降脂疗法中时,依折米布对HIV患者似乎是安全有效的。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录